Cargando…

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression

Immune-checkpoint inhibitors (ICIs) have become the mainstay of treatment for many malignancies. With this new strategy, relevant immune-related adverse events (irAEs) have been reported, some of which can be mistaken for disease progression. To better illustrate the current challenges in diagnosing...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantarotto, Marcos, Barata, Rita, Coelho, Ricardo, Sousa, Virginia, Carvalheiro, Catarina, Rolim, Ines, Garrido, Patricia, GIl, Nuno, Duarte-Ramos, Filipa, Tonin, Fernanda S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364060/
https://www.ncbi.nlm.nih.gov/pubmed/35967142
http://dx.doi.org/10.7759/cureus.26729
_version_ 1784765071262482432
author Pantarotto, Marcos
Barata, Rita
Coelho, Ricardo
Sousa, Virginia
Carvalheiro, Catarina
Rolim, Ines
Garrido, Patricia
GIl, Nuno
Duarte-Ramos, Filipa
Tonin, Fernanda S
author_facet Pantarotto, Marcos
Barata, Rita
Coelho, Ricardo
Sousa, Virginia
Carvalheiro, Catarina
Rolim, Ines
Garrido, Patricia
GIl, Nuno
Duarte-Ramos, Filipa
Tonin, Fernanda S
author_sort Pantarotto, Marcos
collection PubMed
description Immune-checkpoint inhibitors (ICIs) have become the mainstay of treatment for many malignancies. With this new strategy, relevant immune-related adverse events (irAEs) have been reported, some of which can be mistaken for disease progression. To better illustrate the current challenges in diagnosing and managing a patient under adjuvant ICI treatment, we present the case of a 67-year-old female patient with stage IIIB unresectable, epidermal growth factor receptor (EGFR)-mutated, non-small-cell lung cancer who was initially treated with chemoradiotherapy, followed by immunotherapy with durvalumab. During the course of immunotherapy, the patient presented with madarosis and erythematous and endured skin lesions, in addition to lymphadenopathies and pulmonary infiltrates. She was started on first-line palliative treatment with an EGFR tyrosine kinase inhibitor. After reviewing the case, a multidisciplinary team meeting suggested diagnostic procedures, including a transbronchial needle aspiration from mediastinal lymph nodes. The histologic examination showed chronic systemic inflammation and non-caseating granulomas of the sarcoid type. In this case, palliative treatment was suspended and systemic therapy with prednisolone was initiated. The patient became asymptomatic and the previously observed radiologic abnormalities resolved. This case highlights the importance of early recognition and appropriate treatment of irAEs, mainly because these conditions remain poorly understood and are probably underdiagnosed. Considering differential diagnosis is paramount to guide clinical management, despite curative or palliative treatment intent.
format Online
Article
Text
id pubmed-9364060
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-93640602022-08-11 The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression Pantarotto, Marcos Barata, Rita Coelho, Ricardo Sousa, Virginia Carvalheiro, Catarina Rolim, Ines Garrido, Patricia GIl, Nuno Duarte-Ramos, Filipa Tonin, Fernanda S Cureus Oncology Immune-checkpoint inhibitors (ICIs) have become the mainstay of treatment for many malignancies. With this new strategy, relevant immune-related adverse events (irAEs) have been reported, some of which can be mistaken for disease progression. To better illustrate the current challenges in diagnosing and managing a patient under adjuvant ICI treatment, we present the case of a 67-year-old female patient with stage IIIB unresectable, epidermal growth factor receptor (EGFR)-mutated, non-small-cell lung cancer who was initially treated with chemoradiotherapy, followed by immunotherapy with durvalumab. During the course of immunotherapy, the patient presented with madarosis and erythematous and endured skin lesions, in addition to lymphadenopathies and pulmonary infiltrates. She was started on first-line palliative treatment with an EGFR tyrosine kinase inhibitor. After reviewing the case, a multidisciplinary team meeting suggested diagnostic procedures, including a transbronchial needle aspiration from mediastinal lymph nodes. The histologic examination showed chronic systemic inflammation and non-caseating granulomas of the sarcoid type. In this case, palliative treatment was suspended and systemic therapy with prednisolone was initiated. The patient became asymptomatic and the previously observed radiologic abnormalities resolved. This case highlights the importance of early recognition and appropriate treatment of irAEs, mainly because these conditions remain poorly understood and are probably underdiagnosed. Considering differential diagnosis is paramount to guide clinical management, despite curative or palliative treatment intent. Cureus 2022-07-11 /pmc/articles/PMC9364060/ /pubmed/35967142 http://dx.doi.org/10.7759/cureus.26729 Text en Copyright © 2022, Pantarotto et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Pantarotto, Marcos
Barata, Rita
Coelho, Ricardo
Sousa, Virginia
Carvalheiro, Catarina
Rolim, Ines
Garrido, Patricia
GIl, Nuno
Duarte-Ramos, Filipa
Tonin, Fernanda S
The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
title The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
title_full The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
title_fullStr The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
title_full_unstemmed The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
title_short The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
title_sort meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364060/
https://www.ncbi.nlm.nih.gov/pubmed/35967142
http://dx.doi.org/10.7759/cureus.26729
work_keys_str_mv AT pantarottomarcos themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT baratarita themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT coelhoricardo themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT sousavirginia themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT carvalheirocatarina themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT rolimines themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT garridopatricia themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT gilnuno themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT duarteramosfilipa themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT toninfernandas themeaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT pantarottomarcos meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT baratarita meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT coelhoricardo meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT sousavirginia meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT carvalheirocatarina meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT rolimines meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT garridopatricia meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT gilnuno meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT duarteramosfilipa meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression
AT toninfernandas meaningoflymphadenopathiesduringadjuvantdurvalumabafterchemoradiotherapyforlungcancerthinkingbeyonddiseaseprogression